Karvea (Irbesartan)

Karvea (irbesartan) acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and reduce renal stress.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Proteinuric kidney disease: decreases urinary protein excretion and supports renal preservation.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal tissue. By preventing angiotensin II binding, it inhibits vasoconstriction, aldosterone release, and sympathetic activation, leading to reduced peripheral resistance, lower blood pressure, and decreased renal sodium‑water retention.

Irbesartan is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: light‑headed feeling, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: unusual tiredness without exertion.
• Hyperkalemia: elevated blood potassium levels.
• Nasal congestion: stuffy or runny nose.
• Diarrhoea: loose stools.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat.
• Acute renal failure: sudden loss of kidney function.
• Severe hyperkalemia: potassium >6.5 mmol/L with cardiac risk.
• Hepatic injury: jaundice or elevated liver enzymes.
• Myocardial infarction: rare reports of heart attack.
• Anaphylactic reaction: severe allergic response.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for safety.

• Renal function: assess serum creatinine and eGFR before and during treatment.
• Electrolytes: monitor potassium levels, especially with potassium‑sparing agents.
• Pregnancy: contraindicated; teratogenic risk (Category D).
• Concomitant drugs: avoid use with aliskiren in diabetic patients.
• Hepatic impairment: use with caution in moderate liver disease.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren (in diabetes): combined use can increase renal dysfunction and hyperkalemia.
• Dual ARB/ACE‑inhibitor therapy: heightened risk of hypotension, renal impairment, and hyperkalemia.
• Potassium supplements or high‑potassium diet: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely)

• NSAIDs: can blunt antihypertensive effect and affect renal function.
• Lithium: may raise lithium levels, risking toxicity.
• Thiazide diuretics: may increase risk of electrolyte disturbances.
• CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma concentrations.